After outperforming the rest of the field for three straight years, the end of Q2 showed a decided chill in the market toward recent biotech IPOs. Has the window of opportunity closed? If so, what are the ramifications for those who had long anticipated debuts but are currently trading below issue price? Will we see increased partnerships with pharma to fund programs and operations? See a candid discussion on what this will mean for companies looking to fund in the future, for those still in line to IPO by year end and for those now facing the ramifications of falling share prices.
Moderator: John Carroll – Endpoints
- Christiana Bardon – MPM Capital, Oncology Impact Fund
- David Sabow – Silicon Valley Bank
- Simos Simeonidis – RBC Capital Markets
No related posts.